Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii225-viii225 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii225 |
|---|---|
| container_issue | |
| container_start_page | viii225 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Yuki, S. Shinozaki, K. Kashiwada, T. Kusumoto, T. Iwatsuki, M. Satake, H. Tokunaga, S. Emi, Y. Makiyama, A. Kawamoto, Y. Komatsu, Y. Shimokawa, M. Saeki, H. Oki, E. Baba, H. Maehara, Y. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy282.052 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy282_052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419491308</els_id><sourcerecordid>S0923753419491308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2302-6cc0fdd15b7723dd63d4a346f03e45411f697e34d665ef1ca55068416ea7b3973</originalsourceid><addsrcrecordid>eNp9kE1u2zAQhYkiReOmPUA3wVxAEf9lJatESGyjAVxUNdCdQJNUzMKWBJJy4V6nFy0NNV12NcCb994MPoQ-EXxDcMly1XV9p_ODOdE5vcGCvkEzImSZzTEnF2iGS8qyQjB-id6H8ANjLEtavkOXjBIm-VzO0O_NYFS0BlSn9qfgAvQtKBh2KlhYrSDE0ZzOWr3-DsN-DBC9SuKv8aC20PYe4s7CoKKzXQzw08UdLB-_Uhj64KI7WlDmqDqdLiSvt3r0PjnhJZV4p0Gfd_4WPtdVlS8XVb3Iq2q9yL9YX9tNTQQmDx_Q21btg_34d16hzdPjt2qZPa8Xq-r-OdOUYZpJrXFrDBHboqDMGMkMV4zLFjPLBSeklWVhGTdSCtsSrYTAcs6JtKrYsrJgV4hMvdr3IXjbNoN3B-VPDcHNGXgzAW8m4E0CnjLXU2YYtwdr_iVeCSfD3WSw6fOjs74JOrFKQFyiERvTu__U_wFPEJMc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Yuki, S. ; Shinozaki, K. ; Kashiwada, T. ; Kusumoto, T. ; Iwatsuki, M. ; Satake, H. ; Tokunaga, S. ; Emi, Y. ; Makiyama, A. ; Kawamoto, Y. ; Komatsu, Y. ; Shimokawa, M. ; Saeki, H. ; Oki, E. ; Baba, H. ; Maehara, Y.</creator><creatorcontrib>Yuki, S. ; Shinozaki, K. ; Kashiwada, T. ; Kusumoto, T. ; Iwatsuki, M. ; Satake, H. ; Tokunaga, S. ; Emi, Y. ; Makiyama, A. ; Kawamoto, Y. ; Komatsu, Y. ; Shimokawa, M. ; Saeki, H. ; Oki, E. ; Baba, H. ; Maehara, Y.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy282.052</identifier><identifier>PMID: 32136486</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii225-viii225</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32136486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuki, S.</creatorcontrib><creatorcontrib>Shinozaki, K.</creatorcontrib><creatorcontrib>Kashiwada, T.</creatorcontrib><creatorcontrib>Kusumoto, T.</creatorcontrib><creatorcontrib>Iwatsuki, M.</creatorcontrib><creatorcontrib>Satake, H.</creatorcontrib><creatorcontrib>Tokunaga, S.</creatorcontrib><creatorcontrib>Emi, Y.</creatorcontrib><creatorcontrib>Makiyama, A.</creatorcontrib><creatorcontrib>Kawamoto, Y.</creatorcontrib><creatorcontrib>Komatsu, Y.</creatorcontrib><creatorcontrib>Shimokawa, M.</creatorcontrib><creatorcontrib>Saeki, H.</creatorcontrib><creatorcontrib>Oki, E.</creatorcontrib><creatorcontrib>Baba, H.</creatorcontrib><creatorcontrib>Maehara, Y.</creatorcontrib><title>Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE1u2zAQhYkiReOmPUA3wVxAEf9lJatESGyjAVxUNdCdQJNUzMKWBJJy4V6nFy0NNV12NcCb994MPoQ-EXxDcMly1XV9p_ODOdE5vcGCvkEzImSZzTEnF2iGS8qyQjB-id6H8ANjLEtavkOXjBIm-VzO0O_NYFS0BlSn9qfgAvQtKBh2KlhYrSDE0ZzOWr3-DsN-DBC9SuKv8aC20PYe4s7CoKKzXQzw08UdLB-_Uhj64KI7WlDmqDqdLiSvt3r0PjnhJZV4p0Gfd_4WPtdVlS8XVb3Iq2q9yL9YX9tNTQQmDx_Q21btg_34d16hzdPjt2qZPa8Xq-r-OdOUYZpJrXFrDBHboqDMGMkMV4zLFjPLBSeklWVhGTdSCtsSrYTAcs6JtKrYsrJgV4hMvdr3IXjbNoN3B-VPDcHNGXgzAW8m4E0CnjLXU2YYtwdr_iVeCSfD3WSw6fOjs74JOrFKQFyiERvTu__U_wFPEJMc</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Yuki, S.</creator><creator>Shinozaki, K.</creator><creator>Kashiwada, T.</creator><creator>Kusumoto, T.</creator><creator>Iwatsuki, M.</creator><creator>Satake, H.</creator><creator>Tokunaga, S.</creator><creator>Emi, Y.</creator><creator>Makiyama, A.</creator><creator>Kawamoto, Y.</creator><creator>Komatsu, Y.</creator><creator>Shimokawa, M.</creator><creator>Saeki, H.</creator><creator>Oki, E.</creator><creator>Baba, H.</creator><creator>Maehara, Y.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B</title><author>Yuki, S. ; Shinozaki, K. ; Kashiwada, T. ; Kusumoto, T. ; Iwatsuki, M. ; Satake, H. ; Tokunaga, S. ; Emi, Y. ; Makiyama, A. ; Kawamoto, Y. ; Komatsu, Y. ; Shimokawa, M. ; Saeki, H. ; Oki, E. ; Baba, H. ; Maehara, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2302-6cc0fdd15b7723dd63d4a346f03e45411f697e34d665ef1ca55068416ea7b3973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuki, S.</creatorcontrib><creatorcontrib>Shinozaki, K.</creatorcontrib><creatorcontrib>Kashiwada, T.</creatorcontrib><creatorcontrib>Kusumoto, T.</creatorcontrib><creatorcontrib>Iwatsuki, M.</creatorcontrib><creatorcontrib>Satake, H.</creatorcontrib><creatorcontrib>Tokunaga, S.</creatorcontrib><creatorcontrib>Emi, Y.</creatorcontrib><creatorcontrib>Makiyama, A.</creatorcontrib><creatorcontrib>Kawamoto, Y.</creatorcontrib><creatorcontrib>Komatsu, Y.</creatorcontrib><creatorcontrib>Shimokawa, M.</creatorcontrib><creatorcontrib>Saeki, H.</creatorcontrib><creatorcontrib>Oki, E.</creatorcontrib><creatorcontrib>Baba, H.</creatorcontrib><creatorcontrib>Maehara, Y.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuki, S.</au><au>Shinozaki, K.</au><au>Kashiwada, T.</au><au>Kusumoto, T.</au><au>Iwatsuki, M.</au><au>Satake, H.</au><au>Tokunaga, S.</au><au>Emi, Y.</au><au>Makiyama, A.</au><au>Kawamoto, Y.</au><au>Komatsu, Y.</au><au>Shimokawa, M.</au><au>Saeki, H.</au><au>Oki, E.</au><au>Baba, H.</au><au>Maehara, Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii225</spage><epage>viii225</epage><pages>viii225-viii225</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32136486</pmid><doi>10.1093/annonc/mdy282.052</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii225-viii225 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy282_052 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A20%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updated%20analysis%20of%20a%20phase%20II%20study%20of%20SOX%20plus%20trastuzumab%20for%20the%20patients%20with%20HER2%20positive%20advanced%20or%20recurrent%20gastric%20cancer:%20KSCC/HGCSG/CCOG/PerSeUS1501B&rft.jtitle=Annals%20of%20oncology&rft.au=Yuki,%20S.&rft.date=2018-10&rft.volume=29&rft.spage=viii225&rft.epage=viii225&rft.pages=viii225-viii225&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy282.052&rft_dat=%3Celsevier_cross%3ES0923753419491308%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32136486&rft_els_id=S0923753419491308&rfr_iscdi=true |